These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
596 related articles for article (PubMed ID: 18930583)
1. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583 [TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105 [TBL] [Abstract][Full Text] [Related]
3. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024 [TBL] [Abstract][Full Text] [Related]
4. Editorial comment on: Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Novara G Eur Urol; 2009 May; 55(5):1153-4. PubMed ID: 18930580 [No Abstract] [Full Text] [Related]
5. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. Komai Y; Saito K; Sakai K; Morimoto S BJU Int; 2007 Jan; 99(1):77-80. PubMed ID: 16956357 [TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106 [TBL] [Abstract][Full Text] [Related]
7. Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma. Johnson TV; Abbasi A; Owen-Smith A; Young A; Ogan K; Pattaras J; Nieh P; Marshall FF; Master VA J Urol; 2010 Feb; 183(2):480-5. PubMed ID: 20006861 [TBL] [Abstract][Full Text] [Related]
8. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma. Yoo C; Song C; Hong JH; Kim CS; Ahn H J Urol; 2008 Aug; 180(2):486-91; discussion 491. PubMed ID: 18550101 [TBL] [Abstract][Full Text] [Related]
10. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Ito K; Asano T; Yoshii H; Satoh A; Sumitomo M; Hayakawa M Int J Urol; 2006 Nov; 13(11):1365-70. PubMed ID: 17083384 [TBL] [Abstract][Full Text] [Related]
11. Laparoscopic and open partial nephrectomy: a matched-pair comparison of 200 patients. Marszalek M; Meixl H; Polajnar M; Rauchenwald M; Jeschke K; Madersbacher S Eur Urol; 2009 May; 55(5):1171-8. PubMed ID: 19232819 [TBL] [Abstract][Full Text] [Related]
12. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Karakiewicz PI; Hutterer GC; Trinh QD; Jeldres C; Perrotte P; Gallina A; Tostain J; Patard JJ Cancer; 2007 Sep; 110(6):1241-7. PubMed ID: 17639589 [TBL] [Abstract][Full Text] [Related]
13. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Blay JY; Negrier S; Combaret V; Attali S; Goillot E; Merrouche Y; Mercatello A; Ravault A; Tourani JM; Moskovtchenko JF Cancer Res; 1992 Jun; 52(12):3317-22. PubMed ID: 1596890 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Wagner B; Patard JJ; Méjean A; Bensalah K; Verhoest G; Zigeuner R; Ficarra V; Tostain J; Mulders P; Chautard D; Descotes JL; de la Taille A; Salomon L; Prayer-Galetti T; Cindolo L; Valéri A; Meyer N; Jacqmin D; Lang H Eur Urol; 2009 Feb; 55(2):452-9. PubMed ID: 18692951 [TBL] [Abstract][Full Text] [Related]
16. Impact of postoperative C-reactive protein level on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma. Ito K; Yoshii H; Sato A; Kuroda K; Asakuma J; Horiguchi A; Sumitomo M; Asano T J Urol; 2011 Aug; 186(2):430-5. PubMed ID: 21679988 [TBL] [Abstract][Full Text] [Related]
17. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. Margulis V; McDonald M; Tamboli P; Swanson DA; Wood CG J Urol; 2009 May; 181(5):2044-51. PubMed ID: 19286220 [TBL] [Abstract][Full Text] [Related]
18. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival. Teishima J; Ohara S; Shinmei S; Inoue S; Hayashi T; Mochizuki H; Mita K; Shigeta M; Matsubara A Urol Oncol; 2018 Jul; 36(7):339.e9-339.e15. PubMed ID: 29773493 [TBL] [Abstract][Full Text] [Related]
19. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Hashimoto K; Ikeda Y; Korenaga D; Tanoue K; Hamatake M; Kawasaki K; Yamaoka T; Iwatani Y; Akazawa K; Takenaka K Cancer; 2005 May; 103(9):1856-64. PubMed ID: 15779015 [TBL] [Abstract][Full Text] [Related]
20. External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma. Fujii Y; Saito K; Iimura Y; Sakai Y; Koga F; Kawakami S; Kumagai J; Kihara K J Urol; 2008 Oct; 180(4):1290-5; discussion 1295-6. PubMed ID: 18707704 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]